Holdings
Paradigm Biocapital Advisors LP
As of Jun 30, 2026, Paradigm Biocapital Advisors LP reported 27 positions worth US$5.15B. Largest: Revolution Medicines, Inc., Nuvalent, Inc. and Edgewise Therapeutics, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Revolution Medicines, Inc. | 6.36M | US$1.19B | −294K | Jun 30, 2026 |
| Nuvalent, Inc. | 5.92M | US$732M | +600K | Jun 30, 2026 |
| Edgewise Therapeutics, Inc. | 10.2M | US$415M | +2.85M | Jun 30, 2026 |
| Genmab A/s | 13.1M | US$361M | +5.17M | Jun 30, 2026 |
| Spyre Therapeutics, Inc. | 3.84M | US$341M | +1.88M | Jun 30, 2026 |
| Apogee Therapeutics, Inc. | 1.58M | US$209M | +228K | Jun 30, 2026 |
| Oruka Therapeutics, Inc. | 2.14M | US$204M | −176K | Jun 30, 2026 |
| Tango Therapeutics, Inc. | 6.36M | US$199M | +2.35M | Jun 30, 2026 |
| Erasca, Inc. | 9.55M | US$175M | −843K | Jun 30, 2026 |
| Tarsus Pharmaceuticals, Inc. | 2.78M | US$175M | +213K | Jun 30, 2026 |